Small molecule drug, Niraparib combined with abiraterone acetate (AA) and prednisone (P) significantly reduces the risk of disease progression, or death, in patients with a type of prostate cancer, a consultant in Spain has said.
LabTechnologist.com brings you its periodic round up of new product
releases and product news, with new offerings from Aura, Horiba
Jobin Yvon, Integra, Metrohm, Millipore, Promega, Roche and Thermo
Private pharmaceutical firm Tolmar has sold off its pharmaceutical
manufacturing plant in a move to fund the purchase of the US assets
of biopharmaceutical QLT. The plant, sold for $13.6m (€10.5m), will
be leased back to Tolmar under...
Dendreon has finished the construction of its New Jersey
manufacturing facility which it will use to produce its
investigational active cellular immunotherapy for advanced prostate
cancer, hoping to be the first to bring it to patients.
Anticipating a US Food and Drug Administration (FDA) approval this
year, Dendreon has awarded Diosynth Biotechnology with a long-term
contract to supply the recombinant protein antigen component of its
novel vaccine for prostate cancer...
Biopharmaceutical company, Insmed, are to commence clinical
development of a small molecule tyrosine kinase inhibitor, which
has demonstrated anti-tumour activity in preclinical studies of
breast, lung, pancreatic and prostate tumours.
Scientists have determined the precise molecular structure of a
potential new target for treating prostate cancer, a disease driven
in part by abnormal testosterone activity, which affects one in six
Debiopharm of Switzerland has won approval for a three-month depot
formulation of Pamorelin (triptorelin pamoate), a drug to treat
prostate cancer, based on its proprietary polymer-based drug
A new activity-based proteomics screening technique has allowed
scientists to identify active targets and simultaneously screen for
their inhibitors. The screening technique has already revealed that
orlistat, an anti-obesity drug,...
Drug delivery company Atrix Laboratories confirmed this week that
the German regulatory authority, Bundesinstitut fur Arzneimittel
und Medizinprodukte (BfArM), had recently completed a successful
inspection of Atrix's manufacturing...